Alpha Cognition Reports 40% Sequential Revenue Growth on ZUNVEYL Adoption
Event summary
- Alpha Cognition reported $3.5M in Q1 2026 ZUNVEYL revenue, up 40% sequentially from Q4 2025.
- Bottles dispensed grew 23% QoQ to 6,054, with March demand up 29% over February.
- Active prescribers placing repeat prescriptions rose to 75% of the base.
- BEACON study enrollment complete, topline data expected in early Q3 2026.
- Cash position at $54.2M as of March 31, 2026, down from $66M at year-end 2025.
The big picture
Alpha Cognition's Q1 2026 results highlight accelerating adoption of ZUNVEYL, the first new oral Alzheimer's treatment in 15 years. The 40% sequential revenue growth reflects expanding prescriber base and repeat prescriptions, positioning the company for profitability in 2027. Strategic patent wins and Asian approvals via CMS Pharma further strengthen its long-term pipeline. The biopharmaceutical sector continues to prioritize real-world evidence to support payer negotiations and formulary access.
What we're watching
- Commercial Momentum
- Whether Alpha Cognition can sustain the 40% sequential revenue growth pace into Q2 2026, particularly with the fully staffed 60-person sales team now operational.
- Payer Expansion
- The pace at which Medicare Part D implementation accelerates beyond the current 16% of contracted business, as prescription volume increases.
- Clinical Validation
- How BEACON and CONVERGE real-world evidence studies impact payer coverage and prescriber confidence in H2 2026.
Related topics